
Please try another search
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Anna Protopapas | 58 | 2022 | Independent Chairman |
Michael L. Meyers | 74 | 2022 | Independent Director |
Matthew D. Shair | 56 | 2017 | Founder, Head of Scientific Advisory Board & Director |
James R. Porter | 49 | 2020 | CEO, President & Director |
Christy J. Oliger | 55 | 2025 | Independent Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
Aaron Hata | - | - | Member of Scientific Advisory Board |
D. Gary Gilliland | 70 | 2021 | Member of Scientific Advisory Board |
Joseph Pearlberg | 60 | 2021 | Independent Non-Executive Director |
Nancy Kohl | - | - | Member of Scientific Advisory Board |
Alice Tsang Shaw | - | 2024 | Member of Scientific Advisory Board |
Alexander Drilon | - | 2021 | Member of Scientific Advisory Board |
Cameron A. Wheeler | 46 | 2017 | Independent Non-Executive Director |
Grant C. Bogle | 67 | 2024 | Independent Director |
David Ross Camidge | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review